Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCAX Bicara Therapeutics	$9.44 -0.2%	$12.71	$7.80 ▼ $28.09	$514.82M	N/A	545,364 shs	1.04 million shs
PLX Protalix BioTherapeutics	$1.59	$2.36	$0.82 ▼ $3.10	$126.58M	-0.05	543,929 shs	368,082 shs
RLAY Relay Therapeutics	$3.08 +4.4%	$2.79	$1.78 ▼ $10.72	$528.05M	1.65	2.07 million shs	796,078 shs
STOK Stoke Therapeutics	$9.73 +3.2%	$8.32	$5.35 ▼ $17.58	$531.23M	1.2	709,630 shs	453,308 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCAX Bicara Therapeutics	-5.21%	-35.16%	-36.12%	-23.46%	+945,999,900.00%
PLX Protalix BioTherapeutics	+1.92%	-7.02%	-44.21%	-31.76%	+35.90%
RLAY Relay Therapeutics	+3.51%	+3.15%	-9.51%	-9.23%	-56.43%
STOK Stoke Therapeutics	+2.72%	-0.53%	-0.42%	+18.02%	-32.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCAX Bicara Therapeutics	1.8137 of 5 stars	3.5	0.0	0.0	2.0	0.8	0.6
PLX Protalix BioTherapeutics	2.7538 of 5 stars	3.5	0.0	0.0	3.5	0.0	1.9
RLAY Relay Therapeutics	2.4461 of 5 stars	3.4	1.0	0.0	3.5	2.5	0.6
STOK Stoke Therapeutics	3.9937 of 5 stars	3.6	2.0	4.8	3.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCAX Bicara Therapeutics	3.00	Buy	$31.86	237.48% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	843.40% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	473.59% Upside
STOK Stoke Therapeutics	3.29	Buy	$23.20	138.44% Upside

Current Analyst Ratings Breakdown

Latest PLX, STOK, BCAX, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight	$8.00
5/23/2025	BCAX Bicara Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$30.00
5/16/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $41.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
4/17/2025	BCAX Bicara Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underweight	$8.00
4/17/2025	RLAY Relay Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$4.00
4/9/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/7/2025	BCAX Bicara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$45.00 ➝ $44.00
3/27/2025	BCAX Bicara Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$48.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	$59.76M	2.12	$0.09 per share	17.80	$0.47 per share	3.38
RLAY Relay Therapeutics	$7.68M	68.77	N/A	N/A	$5.90 per share	0.52
STOK Stoke Therapeutics	$190.91M	2.78	N/A	N/A	$3.57 per share	2.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCAX Bicara Therapeutics	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/26/2025 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	5.13	N/A	-21.03%	-30.89%	-11.74%	N/A
RLAY Relay Therapeutics	-$341.97M	-$2.23	N/A	N/A	N/A	N/A	-45.75%	-40.75%	8/5/2025 (Estimated)
STOK Stoke Therapeutics	-$104.70M	$0.79	N/A	N/A	N/A	-629.90%	-54.45%	-40.77%	8/5/2025 (Estimated)

Latest PLX, STOK, BCAX, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	BCAX Bicara Therapeutics	-$0.40	-$0.68	-$0.28	-$0.68	N/A	N/A
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million
3/27/2025	Q4 2024	BCAX Bicara Therapeutics	-$0.31	-$0.39	-$0.08	-$0.39	N/A	N/A
3/24/2025	Q4 2024	STOK Stoke Therapeutics	-$0.56	-$0.18	+$0.38	-$0.18	$4.20 million	$22.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCAX Bicara Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCAX Bicara Therapeutics	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	1.98	1.27
RLAY Relay Therapeutics	N/A	18.42	18.42
STOK Stoke Therapeutics	N/A	5.09	5.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCAX Bicara Therapeutics	N/A
PLX Protalix BioTherapeutics	16.53%
RLAY Relay Therapeutics	96.98%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BCAX Bicara Therapeutics	15.50%
PLX Protalix BioTherapeutics	6.50%
RLAY Relay Therapeutics	4.87%
STOK Stoke Therapeutics	11.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCAX Bicara Therapeutics	32	54.54 million	N/A	N/A
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	160.15 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	46.98 million	Optionable

PLX, STOK, BCAX, and RLAY Headlines

Recent News About These Companies

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29 at 7:30 AM | businesswire.com

D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 29 at 3:29 AM | marketbeat.com

Toronto Dominion Bank Invests $35 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 28 at 5:07 AM | marketbeat.com

Biogen maps out $1B biobucks deal with RNAi-focused City Therapeutics

May 27 at 4:12 PM | fiercebiotech.com

Deutsche Bank AG Reduces Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 22, 2025 | marketbeat.com

Toronto Dominion Bank Acquires New Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 21, 2025 | marketbeat.com

Tang Capital Management LLC Buys Shares of 300,000 Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 20, 2025 | marketbeat.com

Chardan Capital Has Strong Forecast for STOK FY2025 Earnings

May 20, 2025 | marketbeat.com

RTW Investments LP Has $56.51 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 18, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Cantor Fitzgerald

May 17, 2025 | marketbeat.com

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

May 16, 2025 | zacks.com

MPM Bioimpact LLC Has $7.57 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 16, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up Following Earnings Beat

May 15, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

May 13, 2025 | zacks.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LP

May 13, 2025 | marketbeat.com

Granahan Investment Management LLC Trims Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 12, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Brokerages

May 12, 2025 | marketbeat.com

DAFNA Capital Management LLC Has $1.89 Million Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 10, 2025 | marketbeat.com

Baker BROS. Advisors LP Increases Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

May 6, 2025 | marketbeat.com

291,795 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by Schonfeld Strategic Advisors LLC

May 6, 2025 | marketbeat.com

Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.4% - Here's Why

April 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, STOK, BCAX, and RLAY Company Descriptions

Bicara Therapeutics NASDAQ:BCAX

$9.44 -0.02 (-0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$9.37 -0.07 (-0.74%)

As of 04:35 PM Eastern

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Protalix BioTherapeutics NYSE:PLX

$1.59 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 -0.01 (-0.88%)

As of 04:45 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Relay Therapeutics NASDAQ:RLAY

$3.08 +0.13 (+4.41%)

Closing price 04:00 PM Eastern

Extended Trading

$3.08 0.00 (-0.16%)

As of 04:44 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$9.73 +0.30 (+3.18%)

Closing price 04:00 PM Eastern

Extended Trading

$9.86 +0.13 (+1.33%)

As of 04:15 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time